Aragen (Formerly GVK BIO) to Partner With Global Biopharma With a Renewed Brand Promise
2.6.2021 14:25:00 EEST | Business Wire | Press release
Aragen Life Sciences (Aragen), formerly known as GVK Biosciences and a leading contract research, development and manufacturing organization, officially marked its transition to a new brand identity. With a legacy of over 20 years of partnering with innovator life sciences companies around the world, Aragen is poised for growth in the outsourced discovery, development, and manufacturing services sector across both large and small molecule platforms.
The global Pharmaceutical CDMO market, valued USD 160.12 billion in 2020, is expected to reach USD 236.61 billion by 2026, registering a CAGR of 6.5%, during the period of forecast (2021-2026), as per a report by Mordor Intelligence. India is seen as a prime location for the CDMO market, and Aragen has demonstrated strong organic growth on the back of deep domain expertise, strong global delivery capabilities, and partnerships with global biopharmaceutical and biotech clients.
Coinciding with its 20 year history and an incoming global investor, Goldman Sachs, Aragen unfolded the new brand. Manni Kantipudi, CEO of Aragen, said, “With an aspiration to be a partner of choice to the life sciences industry, we started humbly 20 years ago. With strategic partnerships and investments over the years, a new investor in the company, and a renewed focus on our customers and solutions, we are ready to take the next leap. Our brand promise of ‘Together Ahead’ and our purpose ‘In every molecule is the possibility for better health’ reflect what Aragen does best – work with our partners and make them successful in the race for better health.”
Elaborating on the new visual brand identity and brand promise, Ramesh Subramanian, Chief Commercial Officer, said, “Our new mark embodies our brand promise, Together Ahead. The seamless coming together of two forms and their collaborative movement, represent our partnerships that enable infinite possibilities for better health. Our symbol which we call ‘AURA’ embodies our distinctive personality — Ambitious, Understated, Resilient and Agile. Aragen’s brand colors are loaded with symbolism and meaning. From the deep blue colour that conveys the possibilities of science, strength and resilience, the transition is made to vibrant orange which symbolizes life, better health, as well as ambition and energy.”
“With this renewed energy and focus, the 3,100+ strong employee base of Aragen, spread across 7 sites in India and overseas, with a pool of over 400 PhDs, is standing ready to continue to serve our existing and new customers in this market.” said Chief Operating Officer, Sudhir Singh.
About Aragen Life Sciences
Aragen Life Sciences Pvt Ltd (Aragen) is a global leader in providing discovery, development and manufacturing solutions for life sciences firms. With a team of over 3100 professionals, and through a network of sites around the world, we offer a seamless, integrated platform to advance customer programs from discovery through commercialization for both small molecules and biologics. Established in 2001, Aragen now serves over 450 customers worldwide across multiple modalities and therapeutic areas.
To view this piece of content from cts.businesswire.com, please give your consent at the top of this page.
View source version on businesswire.com: https://www.businesswire.com/news/home/20210602005569/en/
Contact information
Aragen Life Sciences: Sarat Patanaik, +91 95732 80064, sarat.patanaik@aragen.com
MediaMedic Communications Pvt. Ltd.: Bhavna Pathak, +918830654608, info@mediamedichealth.com
About Business Wire
For more than 50 years, Business Wire has been the global leader in press release distribution and regulatory disclosure.
Subscribe to releases from Business Wire
Subscribe to all the latest releases from Business Wire by registering your e-mail address below. You can unsubscribe at any time.
Latest releases from Business Wire
What Europeans Really Want From Their Next Smartphone13.10.2026 14:01:00 EEST | Press release
If you’ve ever bought running shoes for the runner you hoped to become or luggage for a yet to be planned trip, you’re not alone. New research from Samsung reveals that Europeans1 take a similar aspirational approach when choosing a smartphone. More than two thirds (66%2) of Europeans surveyed1 chose their current smartphone with at least one interest they wanted to pursue in mind, with interests ranging from entertainment and side hustles to gaming, travel and content creation. In fact, almost half (46%3) consider their ambitions when making technology choices, including 24% who say their choices are primarily shaped by the life they aspire to lead. Additionally, almost a third (28%) reported that they chose their current smartphone to better reflect their personal style. Having a variety of options to choose from is important when considering the wide range of aspirations and focuses of European consumers. Big ambitions, everyday needs Europeans1 may be choosing smartphones with futu
Enodia Therapeutics Announces Research Collaboration and License Agreement with Pfizer to Develop Sec61-Targeting Small Molecules13.10.2026 14:00:00 EEST | Press release
Enodia Therapeutics, a biotechnology company developing novel small-molecule therapies for targeted protein degradation at the point of synthesis, today announced it has entered into a research collaboration and license agreement with Pfizer Inc. to discover and develop Sec61 inhibitors. The collaboration aims to accelerate the discovery and advancement of novel small-molecule therapeutics leveraging Enodia’s proprietary platform. Enodia’s proprietary platform enables selective Sec61 Translocon modulation, a novel approach to inhibit disease-driving proteins at the point of synthesis before pathological effects occur, while preserving essential physiological functions. Enodia has built a broad and well-characterized chemical space spanning multiple Sec61 inhibitor families, supported by extensive biological datasets, including proteomics, cryo-EM and tailored cell-line libraries that enable rational small-molecule design powered by machine learning. “Enodia has built a broad platform t
TradingHub Appoints Phil Snow as Chairman13.10.2026 12:00:00 EEST | Press release
TradingHub today announced the appointment of Phil Snow as Chairman, further strengthening the company's leadership as it continues to expand its global presence and invest in innovation across trade surveillance. Phil brings three decades of experience in financial technology, data and analytics, built at FactSet, where he served as Chief Executive Officer from 2015 to 2025. Under his leadership, FactSet more than doubled its revenue, joined the S&P 500 and expanded its products and global presence. The appointment follows TradingHub's recent investment from Nordic Capital and reflects the shared ambition to support the company's next phase of growth while building on the strong foundations established by its leadership team. "Phil is an outstanding appointment for TradingHub, and I am delighted to welcome him as Chairman," said Mike Coats, Chief Executive Officer of TradingHub. "He spent a decade running a global financial data company that serves many of the same institutions we do,
Bregal Milestone Backs Asolvi to Build AI-First Field Service Software for Compliance-Critical Industries13.10.2026 11:00:00 EEST | Press release
Bregal Milestone, a leading European growth private equity firm specialising in software, today announced a majority investment in Asolvi, a provider of field service management (FSM) software for compliance-critical and asset-intensive industries. Bregal Milestone is acquiring its stake from Volpi Capital and Viking Growth. CEO Nick Barnett and the management team are reinvesting alongside Bregal Milestone. Founded in 1991 and headquartered in Trondheim, Norway, Asolvi serves more than 2,000 customers across the UK, DACH, the Nordics, Spain and Latin America. For fire and security installers and utility contractors, Asolvi’s software is the operating system of the business. It schedules engineers, manages maintenance contracts, records inspections, and produces evidence that regulators, insurers and building owners require. Because Asolvi sits at the centre of these workflows, it captures structured data on assets, inspections, parts, and outcomes as jobs are completed. This puts Asol
YouHodler Italy Authorised by CONSOB as a Crypto-Asset Service Provider Under MiCA13.10.2026 10:00:00 EEST | Press release
YouHodler Italy S.r.l., announces that CONSOB, after hearing the Bank of Italy, has authorised it as a crypto-asset service provider (CASP) under Regulation (EU) 2023/1114 (MiCA) and Legislative Decree 129/2024, by resolution no. 24156 of 8 October 2026. The authorisation covers five services: custody and administration of crypto-assets on behalf of clients; exchange of crypto-assets for funds; exchange of crypto-assets for other crypto-assets; execution of orders on behalf of clients; and transfer services for crypto-assets on behalf of clients. With the authorisation, YouHodler Italy serves clients in Italy as a supervised firm under MiCA's client protections: segregation of client crypto-assets, governance and security requirements, pre-contractual information and complaints handling. The company plans to extend its services to all 27 EU Member States through the procedure set out in the Regulation. "The CONSOB authorisation is the result of long and rigorous work with the authoriti
In our pressroom you can read all our latest releases, find our press contacts, images, documents and other relevant information about us.
Visit our pressroom